Plus Therapeutics (PSTV) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stoc ...

HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019. Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Execu ...

Core Insights - Plus Therapeutics, Inc. has appointed Kyle Guse, J.D., M.B.A. to its Board of Directors, where he will chair the Audit Committee and serve on the Compensation Committee [1][2] - Guse brings over 30 years of experience in financial, transactional, and operational roles, including significant positions at Atossa Therapeutics, Inc. and DDC Enterprise Ltd. [2][3] - The company is focused on developing targeted radiotherapeutics for central nervous system cancers, with products like REYOBIQ™ and CNSide, aiming to enhance clinical outcomes [4] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company headquartered in Houston, Texas, specializing in targeted radiotherapeutics for challenging CNS cancers [4] - The company combines image-guided local beta radiation with targeted drug delivery approaches, advancing a pipeline that includes programs for leptomeningeal metastases and recurrent glioblastoma [4] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

HOUSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the online availability of new data on its lead compound REYOBIQ™ (rhenium Re186 obisbemeda) in an abstract for both an oral presentation and a poster to be presented at the Nuclear Medicine and Neurooncology conference to be held May 9-10, 2025 ...

Core Viewpoint - Plus Therapeutics (PSTV) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Company Performance Indicators - The upgrade for Plus indicates an improvement in the company's underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - Plus is expected to earn -$0.99 per share for the fiscal year ending December 2025, representing a year-over-year change of 57.7% [8]. - Over the past three months, the Zacks Consensus Estimate for Plus has increased by 37.9%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade of Plus to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) DELAWARE 33-0827593 (State or Other Jurisdiction ...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Welcome to Plus Therapeutics' Fourth Quarter and Full Year 2024 Results Conference Call. Before we begin, we want to advise you that over the course of the call, including any question-and-answer session, for ...

Core Insights - Plus Therapeutics reported a quarterly loss of $0.67 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.51, representing an earnings surprise of -31.37% [1] - The company generated revenues of $1.41 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 6.49% and showing a slight increase from $1.31 million a year ago [2] - Plus shares have increased by approximately 27.8% since the beginning of the year, contrasting with a -2.9% decline in the S&P 500 [3] Company Outlook - The future performance of Plus Therapeutics will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][5] - Current consensus EPS estimate for the upcoming quarter is -$0.36 on revenues of $1.7 million, while for the current fiscal year, it is -$1.60 on revenues of $5.4 million [7] - The estimate revisions trend for Plus is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Plus belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Indivior PLC, is expected to report quarterly earnings of $0.22 per share, reflecting a year-over-year decline of 40.5% [9]

PLUS THERAPEUTICS, Inc. (PSTV) Q4 2024 Earnings Conference Call March 27, 2025 05:00 PM ET Company Participants Sherry - Conference Call ModeratorDr. Mark Hedrick - President and Chief Executive OfficerAndrew Sims - Chief Financial OfficerEdward Wu - Accedient Capital (Caller)Jason Colbert - Deep World Capital (Caller - via Lindsay)Sean Lee - HC Wainwright (Caller) Dr. Mark Hedrick Final remarks, so after Q&A, just turn it back to me for a few seconds, please. Sherry Good afternoon, ladies and gentlemen. We ...

Exhibit 99.1 Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights UPCOMING EXPECTED EVENTS AND MILESTONES FULL YEAR 2024 FINANCIAL RESULTS • Completed ReSPECT-LM Phase 1 single dose administration trial and determined the maximum feasible and recommended Phase 2 doses. Additional details can be found here • Presented positive ReSPECT-LM Phase 1 interim data for LM at the 2024 SNO Annual Conference. Additional details can be found here • Presented posit ...